Objectives: To investigate the gene expression and molecular pathways implicated in the regulation of the osseous healing process following guided bone regeneration (GBR).
Bone regeneration is a physiological process closely regulated by different growth factors, transcription factors, hormones, and cytokines (Dimitriou et al. 2011) . It takes place in four overlapping phases, which include blood clot formation, inflammation, proliferation and remodelling. The process of bone regeneration has been extensively investigated in fracture studies, where both intramembranous and endochondral ossification are normally observed (McKibbin 1978) . However, most of the key molecules and signalling pathways involved in the complex cascade of events occurring during osseous regeneration, as well as their timing of activation, remain undetected.
The principle of physically sealing off a defect by means of a mechanical barrier to selectively stimulate the healing of a certain tissue type and therefore direct tissue regeneration has been used in reconstructive surgery since the mid-1950s (Murray et al. 1957 ). In 1988, Dahlin et al. (1988) described the guided bone regeneration (GBR) of rat mandibular defects by applying expanded polytetrafluoroethylene (ePTFE) membranes to isolate the defects. The membranes acted as a physical barrier to prevent the ingrowth of soft connective tissue into the bony defects and, at the same time, they allowed the repopulation of the defect only by osteoprogenitor cells coming from the host bone. Since then, GBR has been successfully applied in different pre-clinical and clinical scenarios, using different barrier membranes (non-resorbable or resorbable) associated or not with different bone graft materials (for review see (Donos et al. 2008; Retzepi & Donos 2010) ). The rational of combining a bone graft to a barrier membrane is that it reduces the risk of collapse, act as a scaffold for bone ingrowth and protect the augmented volume from resorption (Donos et al 2002 , Donos et al 2005 .
A critical size defect (CSD) can be defined as the smallest size intraosseous wound that will not heal spontaneously with bone fill but with fibrous connective tissue (Schmitz & Hollinger 1986) . Such defects can be used as successful experimental models to test different procedures or biomaterials for bone regeneration (such as GBR; Donos et al. 2015) . In particular, calvarial CSDs are the most popular ones, owing to the easy access to the skull and the presence of the dura mater and overlaying skin, which enable the creation of standardized defects where biomaterials can be stabilized (Gomes & Fernandes 2011) . Successful regeneration of calvarial CSD has been documented when a membrane has been adapted to both the outer (pericranial) and inner (dural) aspects of the defects (Bosch et al. 1995; Dahlin et al. 1991; Donos et al. 2011a Donos et al. , 2004 Lundgren et al. 1992; Mardas et al. 2002; Moschouris et al. 2016) , but also in cases where a single pericranial membrane was used (Hammerle et al. 1995 (Hammerle et al. , 1992 .
The osseous formation underneath a barrier membrane recapitulates the normal skeletogenesis process and has been histologically described by Schenk et al. (1994) in dog's mandibular defects treated with ePTFE membranes.
The transcriptome associated with the regeneration of rat calvarial CSD defects treated with a dural e-PTFE membrane and a pericranial titanium disc has been previously described (Donos et al. 2011c; Ivanovski et al. 2011a) . Although the principle of selective cell repopulation by the use of a barrier (GBR principle) was applied, the specific projects represented also a model of osseointegration, due to the simultaneous use of a titanium barrier. Remarkably, different transcriptomes associated with 7 and 14 days of healing were identified. On the same year, our group also investigated the role of chemically modified titanium surfaces in modulating gene expression, and described the early and late transcriptional changes associated with hydrophilic and hydrophobic titanium implants Ivanovski et al. 2011b ).
In the past years, gene expression analyses have been used in several studies on bone fractures (Bais et al. 2009; Heiner et al. 2006; Li et al. 2005b; Meyer et al. 2004; Rundle et al. 2006) , bone loading (Kelly et al. 2016; Mantila Roosa et al. 2011; McKenzie et al. 2011; Xing et al. 2005; Zaman et al. 2010) , and on studies investigating differences in gene expression between healthy and diseased bone (Chou et al. 2013; Delgado-Calle et al. 2013) . However, to the best of our knowledge, no study has described gene expression in a model of intramembranous ossification via GBR where only membranes have been employed to seclude the space. We therefore used a similar model to the one applied in our previous publications (Donos et al. 2011c; Ivanovski et al. 2011a ), but without the participating effect of a titanium surface, to better describe the gene expression profiles of the cells participating in early stages of intramembranous osseous regeneration and confirm our previous findings.
Materials and methods

GBR-treated calvarial critical size defects (CSDs)
The study was conducted in accordance with the Animals Scientific Procedures Act 1986, United Kingdom, and approved by the Home Office (PPL number 70/6161). The ARRIVE guidelines for reporting in vivo animal experiments were followed.
Six 6-month-old adult Wistar male rats were used for this experiment. After a couple of weeks of acclimatization at the relevant facility, the experimental surgery was carried out under general anaesthesia of the animals by means of halothane inhalation (3% during induction; 1.5% during maintenance). Following a midline sagittal incision through the skin and the periosteum, extending from the occipital to the frontal region of the calvarium, the cranial vertex was exposed. One standardized, bicortical, 5 mm of diameter CSD was created at the midportion of each parietal bone, by means of a trephine bur General Medical, UK) . As reported by Vajgel et al. (2014) , this defect can be considered as a CSD in rats. The midsagittal suture was not included in the bone defect, in order to preclude its contribution to the bone healing process and to limit the risk of damaging the superior sagittal sinus (Bosch et al. 1995) .
Both defects were treated as follows: an ePTFE non-resorbable membrane (Gore-Tex regenerative membrane, Gore Medical, Arizona, US) was carefully adapted at both the extracranial and the intracranial aspects of the defects, according to the GBR principle. The wound was sutured in layers using a resorbable 5.0 suture (Vicryl â , Ethicon, Cincinnati, OH, USA).
Immediately after the surgery, buprenorphine hydrochloride (Vetergesic, 0.3 mg/mL, Reckitt Benckiser Healthcare, UK) was administered subcutaneously at a dose of 0.04 mg/kg, and enrofloxacin (Baytril â , Bayer, Leverkusen, Germany) was administered subcutaneously at a dose of 2.5 mg/kg. During the postoperative period, antibiotic delivery was continued per os at a dose of 2.5 mg/kg per day for 7 days.
Three animals were randomly euthanized following a healing period of 7 and 15 days.
Gene expression profiling using gene chip microarrays
At sacrifice, the tissue within the defect area was carefully dissected and immediately submerged into 1.0 ml of RNAlater RNA Stabilization Reagent (#AM7024, Applied Biosystems/Ambion, Austin, TX, USA). The tissue retrieved from the two defects in each animal was pooled, in order to have sufficient tissue for the analysis. Total RNA was isolated using RNeasy minicolumns according to the manufacturer's protocol (RNeasy â Mini Kit #74124, Qiagen Ltd., Crowley, UK). The RNA quality and quantity assessment, as well as the amplification and gene chip hybridization, were performed at the Molecular Haematology and Cancer Biology Unit, UCL Institute of Child Health. The concentration of RNA was determined by measuring the absorbance at 260 nm (A 260 ) on an UV/visible wavelength spectrophotometer. The integrity and size distribution of the total RNA were assessed for each sample using the Agilent 2100 Bioanalyzer, Agilent Technologies, and the relative intensities of the 18S and 28S rRNA bands were compared.
Due to the small amounts of starting total RNA (<100 ng), a Two-Cycle Eukaryotic Target Labelling Assay was performed, so to obtain sufficient amounts of labelled cRNA target for analysis (http://www.affymetrix.-com/support/technical/manual/expression_-manual.affx). More specifically, total RNA was firstly reverse-transcribed using a T7-Oligo (dT) Promoter Primer in the first-strand cDNA synthesis reaction. Following secondstrand cDNA synthesis, an unlabelled ribonucleotide mix was used in the subsequent first cycle of in vitro transcription (IVT) amplification and the cRNA was cleaned up. The unlabelled cRNA was then reverse-transcribed in the first-strand cDNA synthesis step of the second cycle using primers. Subsequently, the T7-Oligo (dT) Promoter Primer was used in the second-strand cDNA synthesis to generate double-stranded cDNA template containing T7 promoter sequences. Following clean-up of the doublestranded cDNA, a biotinylated nucleotide analogue/ribonucleotide mix in the second IVT reaction and biotin-labelled cRNA was synthesized, which was subsequently cleaned up and fragmented, resulting in a distribution of RNA fragments sizing 35-200 bases. and image files were created. Based on these image files, the GeneChip â Operating Software (GCOS) computed cell intensity data (.cel files), which were analysed and saved as chp files containing data analysis information for each probe set on the arrays. First-order analysis, quality control and statistical analysis were performed in collaboration with the Bloomsbury Centre for Bioinformatics, UCL department of Computer Science. The Affymetrix MAS 5.0 software was used in order to scale the data to a target intensity of 1500 and to calculate transcript abundance.
Pre-processing of the Affymetrix data included three steps: (i) adjustment of the background consisting of signal intensities caused by autofluorescence of array surface and non-specific binding; (ii) normalization, which included adjustment of the data in order to render the measurements from different arrays comparable; and (iii) summarization, with a view to combine multiple probe intensities for each probe set in order to produce a single expression value for each probe set. GC Robust Multi-array Analysis (GCRMA) was used in the background adjustment step, ignoring the MM (negative probe) intensities and incorporating sequence information from the probes (GC correction). Within-chip and between-chip normalizations were performed in a single step with GCRMA.
The following quality control plots were used to evaluate the Affymetrix data quality:
• Box plots to identify outliers by comparing medians and intensity ranges between samples;
• reproducibility between biological replicates based on density plots comparing the intensity distributions among the arrays;
• histograms of PM vs. MM comparing the intensity distributions values of the PM vs. the MM probes for each chip.
Statistical analysis
The differential gene expression between experimental groups was statistically tested, using the Linear Models for MicroArray (LIMMA) Data Bioconductor package v1.9 and R version 2.4.0. LIMMA applies a modified t-test, which uses a Bayesian approach to make the analysis stable even for small sample numbers. The comparison was performed on GCRMA-normalized data between 7 and 15 days of healing in healthy rats.
Data P-values were corrected using the Benjamini-Hochberg test to control the false discovery rate (FDR) following multiple testing. An adjusted P-value cut-off of 0.05 was used to select differentially expressed genes, which means that all genes with an FDRadjusted value <0.05 were considered as differentially expressed and that the expected proportion of false discoveries was controlled to be less than 5%.
Probe set annotations were derived from the NetAffx website (http://www.affymetrix.-com). Supervised hierarchical clustering was performed using all the probe sets with FDR < 0.05 in any one of the pairwise statistical comparisons. The Manhattan distance metric and average linkages were used for the clustering.
Pathway and Gene Ontology analysis
Pathway and Gene Ontology (GO) analyses were performed using the GENMAPP 2.1 software (Gene Map Annotator and Pathway Profiler). A MAPP is a GENMAPP -produced file that graphically shows the biological relationship between genes or gene products.
A less strict gene selection criterion was applied for the pathway and GO analyses. Hence, for each paired comparison, a data set consisting of the significantly altered genes (P < 0.05) presenting at least twofold change was entered into GENMAPP. The MAPPFinder, an accessory programme working with GENMAPP, and the annotations from the Gene Ontology (GO) Consortium were used to identify underlying processes or mechanisms and global biological trends in gene expression data. More specifically, MAPPFinder calculated the relative amount of differentially expressed genes within each MAPP/GO term and a z-score of the association of gene expression changes with a particular MAPP/GO term (Doniger et al. 2003) . A positive z-score indicates that there are more genes linked to a MAPP/GO term than would be expected by random chance. MAPPs with z-score > 1.96 (which corresponds to a P-value < 0.05) were considered as significantly overrepresented in the differential gene list. In order for a MAPP to be considered for further analysis, it had to include a minimum of five differentially expressed genes.
Results
All surgeries were uneventfull; therefore, all animals could be used for gene expression analysis.
A total of 705 probes were found as significantly upregulated, while 314 probes were downregulated at day 15 vs. day 7 of healing (FDR < 0.05). These probe sets corresponded to 361 genes upregulated and 177 genes downregulated, respectively (Appendix 1). No significant change of regulation was found between the two groups for 30,561 genes.
At day 7, the genes that were upregulated were mainly those responsible for angiogenesis, cytokine activities and inflammatory/immune response, such as Il1b and CD14. Conversely, at 15 days of healing, several genes associated with the ossification process were upregulated, such as BMP and Col11a2.
Supervised hierarchical clustering was performed on a dataset consisting of 2451 probe sets presenting a FDR value < 0.05. The analysis showed a clear separation between the 7 and 15 days specimens, indicating a characteristic gene expression profile per healing time point.
RNA quality assessment
All six samples featured good quality RNA, characterized by well-resolved ribosomal 18S and 28S RNA peaks and 28S/18S band ratio ≥1.8, even though slight degradation was observed in some samples. All RNA samples were considered reliable (Copois et al. 2007) and therefore utilized for transcriptomic analysis.
Quality control
Box plots were utilized in order to examine the distribution of cell intensities corresponding to each array in the set. Following GCRMA normalization, all box plots overlapped fairly well showing that there was no large variation in the intensity values among the GeneChips and no outlier arrays were identified (data not shown).
M vs. A plots (MvA) were utilized to evaluate the reproducibility of biological replicates in the test group (Appendix 2). The plots showed that, although the spread of M values was large, the loess curve did not deviate significantly from the M = 0 axis, which indicated good replicate reproducibility.
Finally, the intensity distributions of the perfect match (PM) and mismatch (MM) values for each GeneChip were assessed with PMvsMM histograms. All samples had typical PM and MM distributions with the cRNA binding to the MM probes less strongly then to the PM probes in all chips, thus confirming a high signal-to-noise ratio (data not shown).
Gene ontology
According to the GO system, genes could be clustered according to three different categories, namely biological processes, molecular functions and cellular components (Doniger et al. 2003) . The GENMAPP and the associated MAPPFinder software (http://www.genmapp.org) were used in this analysis.
The main biological processes differently expressed at day 7 and 15 are listed in Table 1 . In particular, at 7 days, we identified a negative regulation of cellular biosynthetic processes and the negative regulation of apoptosis (programmed cell death), whereas the immune response (adaptive and acute phase immune responses), leucocyte activation, leucocyte migration and cellular localization were clearly upregulated. Remarkably, at this early healing period, a positive regulation of I-KappaB Kinase/NF-KappaB cascade, cell cycle (including the regulation of mitosis, secretion and growth) and angiogenesis was observed (Table 2) .
At day 15, the overexpressed biological processes included cell adhesion, enzyme activity and cell transport (iron ion transport).
In addition, this healing period showed overexpression of signal transduction processes, particularly the negative regulation of Wnt receptor signalling pathway (Table 3) . Cell communication was also well represented through the upregulation of enzyme-linked receptor protein signalling pathways and small GTPase-mediated signal transduction.
Developmental processes were overexpressed at day 15. These include muscle fibre development, anatomical structure morphogenesis and skeletal development (ossification; Table 3 ). Furthermore, cell proliferation and cellular component organization were upregulated at day 15, including cell projection biogenesis, membrane organization (endocytosis) and organelle organization (such as lysosome organization). Finally, cellular metabolic processes, particularly lipid metabolism, polysaccharide biosynthetic process and protein depolymerization were positively expressed at this healing period.
When clustering GO terms according to the molecular functions, carbohydrate binding (glycosaminoglycan), metal ion binding, peptide binding and protein binding (cytokine and heat-shock protein binding) were all overexpressed at 7 days. Furthermore, cytokine and chemokine activities, growth factor activity and enzyme regulatory activity (particularly GTPase activator) were positively regulated. Conversely, at 15 days transcription regulatory activity (more specifically, the translation elongation factor activity), transport activity (such as alpha-type channel activity), RNA binding, integrin binding and catalytic activity were upregulated.
The cellular components predominantly observed at 7 days were endosome, nuclear membrane, nuclear body and receptor complex. At 15 days, cellular activity was more evident, with the overexpression of cell projection, cytosolic small ribosomal subunit, large ribosomal subunit, sarcoplasmic reticulum and cytoskeleton. The extracellular matrix, particularly the basal lamina, was also overexpressed at this later stage of bone regeneration (Table 3) .
Pathway analysis
A total of 1019 probe sets (of 31,099) met the P < 0.05 criteria of significantly different expression and minimum of twofold change between the groups. Among these probes, 735 were linked to a MAPP system, which corresponded to a total of 267 genes with differential expression linked to a MAPP. The z-score was therefore calculated with R = 267 distinct genes and N = 3610 genes overall linked to the MAPP system. Six pathways were significantly enriched when analysing the genes differentially expressed at day 15 vs. day 7 (z-score≥1.96) ( Table 4 ). The cytokines and inflammatory response pathway, as well as the IL-1 NetPath 13 were particularly upregulated at day 7. Conversely, the ribosomal proteins were particularly upregulated at day 15.
Inflammatory and immune response
A clear upregulation of the immune and inflammatory responses was found at day 7 of healing compared to 15 days (Fig. 1) . Individual genes that were significantly upregulated include IL6, IL1a and IL1b. Interestingly, the gene encoding for Traf6 protein, a signal transducer in the NF-kappaB pathway, the granulocyte colony-stimulating factor receptor (Csf3r) that initiate cell proliferation and differentiation into mature neutrophilic granulocytes and macrophages, and the C-C motif chemokine 3 (Ccl3), which is involved in the recruitment and activation of polymorphonuclear leucocytes, were also overexpressed at 7 days of healing.
Cell development and cell cycle
A number of genes involved in cell cycle regulation were upregulated at day 7, including cyclin B1 (Ccnb1), cell division control protein 2 homologue (Cdc2a) and transforming acidic coiled-coil-containing protein 3 (Tacc3) ( Table 2) .
GO terms related to cellular compartments were also significantly upregulated at day 7, including the Endosome, nuclear membrane, extracellular space and receptor complex. More specifically, genes that were upregulated within these pathways were the low-density lipoprotein (LDL) receptor (Ldlr), a mosaic protein that mediates the endocytosis of cholesterol-rich LDL (Gent & Braakman 2004 ) and cluster of differentiation 14 (cd14), a component of the innate immune system.
At 15 days of healing, a more complex cellular activity was evident. Genes that were upregulated at this later healing stage include the Rho/Rac guanine nucleotide exchange factor FGD1 (Fgd1), which regulates the secretory transport of bone-specific proteins from the Golgi complex (Egorov et al. 2009 ), the platelet-derived growth factor (PDGF), a mitogenic and chemotactic factor for osteoblasts and perivascular cells (Lieberman et al. 2002) , alpha spectrin 2 (Spna2), a filamentous protein that plays an important role in membrane organization and in actin dynamics (Rotter et al. 2005) , and growth hormone receptor (Ghr), a transmembrane receptor for growth hormone (GH), known to play a major role in bone metabolism (Svensson et al. 2001) . Another important gene upregulated at day 15 was insulin-like growth factor-1 (IGF1).
Moreover, GO terms related to specific cellular components, such as cytosolic small ribosomal subunit, large ribosomal subunit and basal lamina were upregulated at day 15. Genes related to these cell activities include Laminin subunit alpha-2 (Lama2) and ribosomal protein L7 (Rpl7). Remarkably, S100 calcium-binding protein A1 (S100a1) was also upregulated.
In the present analysis, the anti-apoptosis GO term was upregulated at day 15. In particular, among the genes positively represented, we found Activating transcription factor 5 (Atf5) and Cryab gene, encoding alpha crystalline B chain (Table 3) .
Cell metabolism
At day 15 of healing, many GO terms related to cell metabolism were upregulated, including cellular biosynthetic processes, fatty acid oxidation, polysaccharide synthesis, protein translation and regulation of transcription. Genes encoding various 60S ribosomal proteins (Rpl3, Rpl7, Rpl22, Rpl15 and Rpl37) and 40S ribosomal proteins (Rps6, Rps29, Rps11 and Rps3a) were also upregulated (Table 3 ). In addition, the 15-day samples showed an upregulation of GO terms related to catalytic activity, hydrolase activity and lyase activity.
Pathways associated with bone formation
At day 15, the GO terms ossification and skeletal development were significantly overexpressed. The pathways involved in bone formation could be distinguished in the following groups:
a) Extracellular matrix formation
The GO terms extracellular matrix, basement membrane and basal lamina, were upregulated at day 15. For instance, Lama2, encoding laminin alpha-2 and Dmp-1, encoding dentin matrix protein 1, were found as upregulated (Table 3) .
b) Growth factors and hormones
Several genes encoding growth factors and hormones involved in bone formation were significantly upregulated at day 15, including BMP3, BMP4 and Thra_v2 (thyroid hormone receptor alpha, variant 2), Bglap2 (Bone gamma-carboxyglutamate protein 2), Ptn (pleiotrophin) and Fgfr2 (fibroblast growth factor receptor 2) (Table 3 ).
c) Angiogenesis
The GO term angiogenesis was upregulated as early as 7 days. Table 4 . Significantly enriched pathways (z-score > 1.96) at 15 vs. 7 days of healing, with genes presenting significantly differential expression (P < 0.05) and a minimum twofold change in each comparison. The percentage of differentially expressed genes and the percentage of genes present in each specific pathway are shown. Red indicates genes upregulated at 15 days, green indicates genes upregulated at 7 days, and yellow indicates genes significantly overexpressed by both groups Fig. 1 . Schematic overview of the cytokines and inflammatory response genes. This pathway was mainly overexpressed at day 7. Red indicates genes significantly upregulated at 15 days of healing. Green indicates genes significantly upregulated at day 7 of healing (P < 0.05 and greater than twofold differential expression).
In particular, genes such as Angptl4 and Hypoxia inducible factor 1, alpha subunit (Hif1a) were overexpressed at this early healing period (Table 2 ).
d) Enzyme activity
GO terms related to enzyme activity and which have an effect on bone metabolism were upregulated at day 15. These include MAPK activity and transmembrane receptor protein tyrosine kinase signalling.
More specifically, genes that were differentially expressed include encoding transforming growth factor-b3 (Tgfb3) and Map2k6, encoding mitogen-activated protein kinase kinase 6.
The transmembrane receptor protein tyrosine kinase signalling was found to be significantly expressed throughout the observed healing periods. Genes differentially expressed in this pathway at day 7 include suppressor of cytokine signalling 3 (Socs3) and protein tyrosine phosphatase non-receptor type 1 (Ptpn1). Conversely, significantly upregulated genes in this pathway at day 15 include epidermal growth factor receptorrelated protein 2 (Erbb2) and platelet-derived growth factor C polypeptide (Pdgfc).
e) Wnt signalling pathway-related genes
At day 7, there was a positive regulation of the Wnt signalling pathway, a key mechanism in bone repair and regeneration. Conversely, at day 15, there was an upregulation of genes encoding Dkks (DKK3) and Sfrps (Frzb), which are both Wnt antagonists (Table 3) .
Discussion
The aim of the present study was to provide an insight into the gene expression profiles and biological pathways regulating the healing events following GBR application in calvarial CSDs. Microarray analysis of gene expression allowed a comprehensive and global overview of gene expression during the early stages of intramembranous ossification following GBR. In particular, the use of Affymetrix GeneChip enabled the analysis of the entire rat transcriptome, which represents over 28,000 well-substantiated rat genes.
The calvarial CSD model is a welldescribed and popular model for studying GBR (Donos et al. 2015) . Previous histological studies have described that bone regeneration under a barrier membrane follows the normal stages of intramembranous osseous healing, with the blood clot soon replaced by a loose connective tissue and progressively organized into woven bone first and eventually into matured lamellar bone (Donos et al. 2004; Schenk et al. 1994) .
Studies of genomewide expression in fracture healing have demonstrated the complexity of osseous regeneration and have started to elucidate some of the key signalling pathways involved (Hadjiargyrou et al. 2002; Li et al. 2005b; Rundle et al. 2006) . In previous studies, the transcriptomes associated with a model of GBR and osseointegration have been described and a number of genes and pathways differently expressed at different healing stages have been suggested (Donos et al. 2011c; Ivanovski et al. 2011a ).
In the current investigation, the comparison of the 7 and 15 days transcriptomes showed a different regulation of several signalling pathways.
The choice of these healing periods is supported by previous studies that have showed how these early time points are critical for skeletogenesis, since they are located in the stage where the initial inflammation is gradually overlapped by a progressive maturation of the granulation tissue into woven bone (Donos et al. 2011c; Ivanovski et al. 2011a; Rundle et al. 2006) .
A clear upregulation of the immune and inflammatory responses was found at day 7 of healing compared to 15 days (Fig. 1) . The inflammatory response is an important phase in early osseous wound healing, since it is responsible for the activation of various growth factors and cytokines, which attract the osteogenic cells into the wound and regulate the healing process (Schmidt-Bleek et al. 2012) . Remarkably, genes that were significantly upregulated include IL6, IL1a, IL1b, Traf6, Csf3r and Ccl3, which are all wellrecognized key pro-inflammatory mediators, known to elicit migration and activation of inflammatory cells (Darnay et al. 1999; Duplomb et al. 2007; Eyles et al. 2006; Moser & Willimann 2004) .
The upregulation of immune and inflammatory genes and of the NF-kB pathway at day 7 of intramembranous bone healing is in agreement with previous in vivo fracture healing studies (Bais et al. 2009; Rundle et al. 2006 ) and with our previous findings in a similar model (Donos et al. 2011c; Ivanovski et al. 2011a) .
Angiogenesis was found upregulated as early as 7 days (Table 2 ). Blood vessel formation is a well-recognized requirement for regeneration and angiogenic factors may interact with bone cells to promote osseous formation (Portal-Nunez et al. 2012 ). Genes such as Angptl4, a member of the angiopoietin/angiopoietin-like gene family, were upregulated at this early healing stage. The encoded protein is a serum hormone directly involved in regulating glucose homoeostasis, lipid metabolism and insulin sensitivity, and it also acts as an apoptosis survival factor for vascular endothelial cells. Another interesting upregulated gene at 7 days was Fmsrelated tyrosine kinase 1 (Flt1), encoding the vascular endothelial growth factor receptor 1. Vascular endothelial growth factor (VEGF) is an angiogenic and vasculogenic factor, and its presence is crucial at the onset of bone formation.
Our data showed that cellular activity started to be evident at day 7, with the upregulation of genes encoding mainly the cell membrane and cell receptors required at this early stage of healing. At day 15, more complex cellular activities became overexpressed, including the various cellular organelles (particularly ribosomes) for the synthesis of various tissue components. The upregulated genes were mainly encoding ribosomal proteins, growth factors and hormones necessary for bone formation. The high ribosomal activity found at 15 days is most likely related to the increased collagen synthesis at this more advanced stage of osseous healing.
These findings corroborate previous in vivo fracture healing studies, where skeletal development genes were well represented at 11 days of healing (Rundle et al. 2006) . They are also in agreement with the healing events histologically described in calvarial CSDs treated with GBR, in which bone islands start to appear within the granulation tissue by the second week of healing (Hammerle et al. 1995) .
Among the pathways involved in bone formation that we found as upregulated at 15 days of healing, we distinguished genes involved in extracellular matrix formation, growth factors, hormones and enzymatic activity. Remarkably, among the upregulated genes encoding growth factors and hormones, we noticed BMP3, BMP4, Thra_v2, Bglap2, Ptn and Fgfr2. These results significantly mirror our previous findings in a similar model, where BMP2, BMP3, Bglap2, Fgfr1, Fgfr2, Thra and Ptn were found overexpressed at 14 days of healing under a polished titanium barrier (Donos et al. 2011c; Ivanovski et al. 2011a) . The above upregulated gene expression may be of particular importance due to the role that those hormones and growth factors play in bone formation.
For instance, bone morphogenetic proteins (BMPs) form the largest group of the TGF (transforming growth factor)-b superfamily. They regulate differentiation of mesenchymal cells into components of bone, cartilage or adipose tissue. In particular, BMP4, which we found as upregulated at 15 days, is involved in bone and cartilage development and fracture repair (Shore et al. 1998) .
Thyroid hormones are required for skeletal development and for the establishment of peak bone mass. They are also required to maintain optimal bone strength. Their action in the bone is mediated by thyroid hormone receptor alpha (or Thra) (Williams 2009 ).
Fibroblast growth factors (FGFs) are also important players in wound healing. FGF1 and FGF2 stimulate angiogenesis and the proliferation of fibroblasts that are responsible for the formation of the granulation tissue in the early wound healing process (Bottcher & Niehrs 2005) . Their receptor, FGFR2, which in the present study was upregulated at day 15, was also found to be expressed on preosteoblasts and osteoblasts during the later phase of bone formation (Eswarakumar et al. 2002) .
Pleitrophin (PTN), also known as osteoblast stimulating factor-1 (OSF-1), is a secreted heparin-binding peptide expressed in mesodermal and neuro-ectodermal cells during development. PTN is synthesized by osteoblasts at an early stage of osteogenic differentiation and is present at sites of new periosteal and endochondral bone formation (Petersen & Rafii 2001) . We reported an overexpression of this peptide at day 15. In vitro, PTN stimulates osteogenic differentiation of mouse bone marrow cells (Tare et al. 2002) and recruits osteoblasts by chemotaxis (Li et al. 2005a ).
The Bglap2 gene, which was significantly overexpressed at day 15 compared to day 7, encodes the bone gamma-carboxyglutamate protein 2, or osteocalcin, a non-collagenous protein found in bone and dentin. Osteocalcin is a marker of mature osteoblasts, and it regulates osteoblast-osteoclast interaction and bone resorption; recent evidence suggests that it can also have an endocrine function, by regulating glucose and lipid homoeostasis (Patti et al. 2013) .
Among the GO terms upregulated at 15 days and relating to enzyme activity, we found MAPK activity and transmembrane receptor protein tyrosine kinase signalling. The mitogen-activated protein kinases (MAPK) pathway transduces signals from several growth factors or adhesion molecules (e.g. EGF, FGF, IGF, alpha-2 and alpha-5 integrins), as well as BMPs via unknown molecular mechanisms and is essential for skeletogenesis (Greenblatt et al. 2010 ).
The transmembrane receptor protein tyrosine kinase signalling was found to be significantly expressed throughout the observed healing periods. Phosphorylation of proteins by kinases is an important mechanism in signal transduction for regulation of cellular activity (Hanks et al. 1988) . Genes differentially expressed in this pathway at day 7 include Socs3, a negative regulator of cytokine activity, and Ptpn1, which was shown to modulate macrophage activation in vivo (Heinonen et al. 2006) . Significantly upregulated genes in this pathway at day 15 include Erbb2, a cell membrane surfacebound receptor tyrosine kinase involved in the signal transduction pathways leading to cell growth and differentiation (Olayioye 2001) , and Pdgfc. The exact role of the latter protein is still unknown, but Li et al. (2005c) reported that it could induce differentiation of bone marrow cells into endothelial cells and stimulate migration of endothelial cells. To the best of our best knowledge, the expression of this gene was not documented previously in the bone healing process.
Interestingly, at day 7, there was a positive regulation of the Wnt signalling pathway, while at day 15, we found an overexpression of genes encoding inhibitors of the canonical Wnt pathway (such as DKK3 and Frzb). Genetic studies in human and animal models suggested that the canonical Wnt pathway plays an important role in skeletal development, osteoblast differentiation and bone formation (Logan & Nusse 2004) . This finding mirrors our previous results, where we described a significant upregulation of some inhibitors of the canonical Wnt pathway (DKK3, Axin2, Apc2) at 14 days of healing under a polished or a rough titanium barrier (Donos et al. 2011c; Ivanovski et al. 2011a ).
In conclusion, our results demonstrated that the gene expression profiles of the cells partaking in intramembranous bone formation following GBR are different depending on the different healing stages. The model showed to be reliable and reproducible, considering the significant overlap of results with previous studies from our group using the same CSD model but with a different barrier (titanium polished or rough disc) and the similarities with previous studies using the bone fracture model. It would be interesting to evaluate the same GBR model with other types of barriers, such as resorbable membranes or titanium barriers with modified surface characteristics, to understand whether the barrier per se could affect, at any stage, the gene expression profile of the osseous wound.
We acknowledge that this study presents with some limitations and that was mainly performed to test a model for gene expression analysis associated with GBR. Only two time periods were considered, so results can only be interpreted in the context of up/downregulation of genes between these two time points. No histological analysis was performed, which could correlate gene expression with phenotypic changes within the defects during osseous regeneration. Nevertheless, previous studies have histologically described the early healing events taking place during the regeneration of bone defects treated with different barrier membranes for GBR (Hammerle et al. 1995; Zahedi et al. 1998) . The gene expression profiles were identified through the use of oligonucleotide microarrays, in which probes set on a solid planar surface are used to investigate different parts of the sequence of the same gene. This means that the analysis was performed at the transcriptome level, not on the protein level. The transcriptome reflects only genes that are being actively expressed (transcripted) by the cells, but the levels of mRNA are not directly proportional to the expression level of the proteins they code for. The future step will therefore be to combine these results with proteomic data, to have a broader and more precise picture of the mechanisms involved in bone regeneration. Earlier and later healing periods should also be investigated by future studies.
Finally, in the present investigation, there was no control group, where no membrane was applied to the defects. However, the healing in such a control group would lead to fibrous tissue formation (instead of intramembranous osseous formation), as extensively reported in the literature (Donos et al. , 2004 Mardas et al. 2008) .
Within the aforementioned limitation, this study improved our understanding of the signalling pathways regulating bone regeneration and suggested a number of genes differently expressed at different healing stages. The identified genes may have a potential important role in regulating osteogenesis and may therefore constitute attractive candidates for the development of novel anabolic and/or regenerative therapies.
